When will you recommend enfortumab vedotin plus pembrolizumab as first-line treatment of metastatic urothelial carcinoma for cisplatin-ineligible patients?  

Will you use it rather than a carboplatin-containing regimen?



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice
Comments
Medical Oncologist at NYU Winthrop Hospital
Great review @Guru 
Sign in or Register to read more